|
gptkbp:instanceOf
|
gptkb:drug
peptide
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:ATCCode
|
B06AC02
|
|
gptkbp:brand
|
gptkb:Firazyr
|
|
gptkbp:CASNumber
|
30308-48-4
|
|
gptkbp:contraindication
|
hypersensitivity to icatibant
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developer
|
gptkb:Shire
|
|
gptkbp:eliminationHalfLife
|
1-2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C59H89N19O13
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
icatibant
|
|
gptkbp:indication
|
acute attacks of hereditary angioedema
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
bradykinin B2 receptor antagonist
|
|
gptkbp:metabolism
|
proteolytic enzymes
|
|
gptkbp:molecularWeight
|
1304.5 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
6852376
DB06196
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
fever
dizziness
injection site reaction
|
|
gptkbp:status
|
FDA approved
EMA approved
|
|
gptkbp:synonym
|
HOE-140
|
|
gptkbp:UNII
|
8Y164V895Y
|
|
gptkbp:usedFor
|
gptkb:hereditary_hemorrhagic_telangiectasia
|
|
gptkbp:bfsParent
|
gptkb:hereditary_hemorrhagic_telangiectasia
|
|
gptkbp:bfsLayer
|
6
|